Compound reference

Tirzepatide Dosage Guide 2026: Clinical Trials vs Reported Use

By the Decadewise team Education only Last reviewed 19 July 2026 6 cited sources

Short answer

What it is: tirzepatide is a once-weekly injectable that activates two incretin receptors at once: GIP and GLP-1, with no meaningful glucagon activity in the mix.

The trial doses: the phase 3 SURMOUNT-1 trial (Jastreboff, NEJM 2022) tested three once-weekly doses over 72 weeks:

5mg
10mg
15mg

The headline number: the 15mg arm lost the most weight, about 20.9% at 72 weeks, against 3.1% on placebo.

The catch: doses are written in milligrams. Syringes read in units.

Why it trips people: the two only agree once you know the concentration in your vial.

The real risk: get the concentration wrong and a normal dose looks twenty times bigger on paper. That mismatch, not the milligrams, is what drives the panic posts we've read.

The status: FDA approved as Mounjaro for type 2 diabetes and Zepbound for weight management. Research vials are not the approved product. Every trial figure comes straight from the cited papers, DOIs at the bottom.

The calculator

How it works: enter a vial size, a water amount, a syringe type, and a dose in milligrams. It returns the concentration, the volume, and the reading on the barrel.

Units converter

Converts the numbers you type. It does not recommend a dose.

Vial amount mg Bacteriostatic water mL Syringe type Dose you want to convert mg

Concentration5 mg per mL

Volume to draw0.5 mL

Reads as50 units

Arithmetic only. Check the result against your own vial, your own reconstitution, and your own syringe before you trust any unit count.

On this page

Short answer Calculator Reported use What did the trials do? Trial dose vs internet dose How the units math works How many units is 2.5mg? What's not known yet? The safety picture How this page is sourced The disclaimer

Community reports, not a protocol

What do users report running?

The source: this section is what the community reports.

The reported start: the schedule in the posts tracks the label: 2.5mg once weekly for the first four weeks, then 2.5mg steps.

The hold pattern: plenty of posters describe staying at 2.5mg or 5mg long past the four-week mark while weight keeps moving, instead of stepping up on schedule.

The splitting talk: threads discuss splitting the weekly dose into two smaller injections. No controlled trial has studied that pattern.

The units confusion: the loudest cluster is research-vial math. The same "50 units" gets quoted as 2.5mg by one poster and 5mg by the next, because the vials and water amounts differ.

The churn: posters describe cycling between brand pens, compounded vials, and research suppliers as cost and availability shift around them.

The regulator's count: the FDA has logged more than 730 adverse event reports tied to compounded tirzepatide as of May 31, 2026. Community reports are not controlled data.

Reports, not a protocol: everything above is what users post. It is not what the trials ran and not what the label says.

Peer-reviewed trial data

What did the trials do?

The setup: the pivotal obesity trial, SURMOUNT-1 (Jastreboff et al., New England Journal of Medicine, 2022), enrolled 2539 adults without diabetes across four arms, weekly tirzepatide or placebo, for 72 weeks. The arms in the table below.

The escalation: the trial built in a 20-week dose-escalation period. The current label schedule starts at 2.5mg once weekly for the first four weeks, moves to 5mg, then steps up by 2.5mg when more effect is needed, to a 15mg maximum.

Why steps matter: gastrointestinal side effects were the most common adverse events in the trial, and they occurred primarily during dose escalation.

Arm	Weekly dose	Escalation
placebo	0mg	none
low	5mg	2.5mg steps every 4 weeks
mid	10mg	2.5mg steps every 4 weeks
top	15mg	2.5mg steps every 4 weeks

Four arms, weekly tirzepatide or placebo, 72 weeks. SURMOUNT-1, Jastreboff et al., NEJM 2022.

The result: the 15mg arm brought mean body weight down 20.9% at 72 weeks, against 3.1% on placebo. The 10mg arm was down 19.5% and the 5mg arm 15.0%.

The deeper cut: 57% of the 15mg arm lost at least a fifth of their body weight, against 3% on placebo.

The fine print: these are mean percentage changes straight from the trial abstract.

The mechanism: it has its own paper, Coskun et al., Molecular Metabolism, 2018, the discovery and first-in-human work. Tirzepatide, LY3298176 in the papers, is a dual agonist at two receptors: GIP and GLP-1. Its glucagon-receptor activity is minimal, per the discovery paper.

The head-to-head: the SURPASS-2 trial (Frias et al., New England Journal of Medicine, 2021) ran 1879 people with type 2 diabetes for 40 weeks against semaglutide 1mg. HbA1c fell 2.01 to 2.30 percentage points across the three doses, against 1.86 on semaglutide, and tirzepatide was noninferior and superior at all three doses.

And the weight: down up to 5.5kg more than semaglutide at the 15mg dose.

The monotherapy trial: SURPASS-1 (Rosenstock et al., The Lancet, 2021) put 478 people with type 2 diabetes controlled only by diet and exercise on tirzepatide or placebo for 40 weeks. HbA1c dropped 2.07 percentage points at 15mg while placebo barely moved, and bodyweight fell 7.0 to 9.5kg depending on dose.

The diabetes obesity trial: SURMOUNT-2 (Garvey et al., The Lancet, 2023) ran 938 people with overweight or obesity and type 2 diabetes for 72 weeks: down 12.8% at 10mg and 14.7% at 15mg, against 3.2% on placebo.

Don't merge these trials' numbers: different populations, different timepoints, different comparators.

20.9%

mean body weight down at 72 weeks, 15mg arm

19.5%

down at 72 weeks, 10mg arm

3.1%

on placebo at 72 weeks

2539

adults across four arms, none with diabetes

SURMOUNT-1 obesity trial, Jastreboff et al., NEJM 2022.

Is the trial dose the same as what people post?

The usual dodge: most pages we have checked either gloss over the question or post a schedule with no trial behind it. We're doing neither.

What the trial's schedule is for

What it's for: the trials exist to answer research questions: does the drug beat placebo, does it beat semaglutide, and how much does the dose matter. That is why a 5mg arm sits next to a 10mg and a 15mg arm, on purpose, with a placebo arm too.

What it is: dose-ranging evidence. Not a recommendation.

What people run online

What the posts show: reported titrations drift from the label schedule in both directions: slower holds at 2.5mg or 5mg, or faster steps when a vial is running out. The trials and the label test one schedule; the forums test everything else.

The cost logic posted: a research vial costs the same drawn slow or fast, which pushes toward stretching it. Brand pens price per month, which pushes the other way.

Which of those numbers fits you is not something we will tell you.

The real question: it comes down to your body, your risk tolerance, and a doctor who knows your history. What this page can hand you is what the trials published, what the label says, and the math behind a dose; the rest is yours to settle with someone qualified.

How does the units math work?

The point: run the math once, in general terms, with no dose attached to you.

Example one: say a 10mg research vial gets reconstituted with 2mL of bacteriostatic water. That's 5mg per mL, or 5,000mcg per mL.

The syringe side: a U-100 insulin syringe holds 100 units per mL, so one unit is 1/100th of a mL, which here is 50mcg, or 0.05mg. From there: 2.5mg is 50 units, 5mg is 100 units.

Change one thing: reconstitute the same 10mg vial with 1mL instead of 2mL. Concentration doubles to 10mg per mL.

What changes: each unit now equals 0.1mg instead of 0.05mg. The same 2.5mg is now 25 units, not 50.

The forum trap: that "50 units" someone read on a forum could be 2.5mg at one concentration and 5mg at another.

Same 10mg vial, two reconstitutions, on a U-100 syringe

Water added	Concentration	1 unit equals	What the article works out
2mL	5mg per mL (5,000mcg per mL)	0.05mg (50mcg)	2.5mg is 50 units, 5mg is 100 units
1mL	10mg per mL	0.1mg	2.5mg is 25 units, not 50

Syringe scale, before any concentration math

Syringe	Units per mL	1 unit equals
U-100	100 units per mL	0.01mL
U-40	40 units per mL	0.025mL

At the same unit mark, the U-40 pulls 2.5x the drug the U-100 does.

The brand side: a Mounjaro single-dose pen or single-dose vial delivers its dose in a fixed 0.5mL, straight from the label. That fixed 0.5mL reads as 50 units on a U-100 syringe; the multi-dose vial and the KwikPen deliver 0.6mL per dose, 60 units. The units question only exists for vials you mix yourself.

The other trap: the syringe itself. Insulin syringes read in units at two common scales, and concentration has nothing to do with it.

The two common scales: U-100 marks 100 units per mL, one unit is 0.01mL. U-40 marks 40 units per mL, one unit is 0.025mL.

The 2.5x problem: draw on a U-40 while thinking in U-100 numbers and each unit pulls 2.5 times the volume you intended. Same vial, same concentration, same "40 units" on the barrel.

Confirm which syringe is in your hand before any of this arithmetic matters.

Both halves: that is the entire units-versus-mg problem in one line. The barrel never lies. It just does not know your vial or its own scale; you do.

How many units is 2.5mg of tirzepatide?

The short answer: it depends on the concentration. At 5mg per mL (a 10mg vial plus 2mL of water), 2.5mg reads as 50 units on a U-100 syringe. At 10mg per mL (the same vial plus 1mL), 2.5mg reads as 25 units.

The rule: no milligram amount has one universal units number. Concentration first, syringe scale second, arithmetic third, or run it in the calculator above.

What's not known yet?

The status: tirzepatide is FDA approved, twice over. Mounjaro for type 2 diabetes since 2022, Zepbound for chronic weight management since 2023, with an obstructive sleep apnea indication added in 2024.

What that means: the approval is not the caveat here. The vial is. Everything in the trials, the label schedule, and the boxed warning describes the approved product; a research-grade vial is not it.

The real gaps:

No controlled-trial data on the community patterns: dose splitting, long holds below the label steps, research-vial titration. None of it has been studied.
No verified data on stopping and restarting.
No published head-to-head between brand pen and research vial. The trials ran the same molecule the brands sell, nothing else.

Anyone who claims otherwise is guessing.

The biggest gap: in our read, one gap outweighs every dose number on this page. A research-grade vial arrives with no independent verification of its contents.

All taken on trust: identity, purity, sterility, and the actual labeled strength.

The quiet one: a mislabeled concentration silently breaks every units calculation above. The math is only as honest as the mg figure on the label.

The real worry: that is not a dosing question, a sourcing question, and that is what would keep us up first.

How this page is sourced

No secondary summaries: every trial figure above comes straight from the abstracts of the cited papers. None of it is lifted from a summary site.

The six sources: five papers and the current prescribing information, with DOIs and PubMed IDs below. Pull them yourself, and check every number here against theirs.

The standard: the full sourcing and citation-verification standard for this site lives on the methodology page. Corrections to any number on this page land there first.

Last reviewed: 19 July 2026.

1
Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038. PMID 35658024.
2
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519. PMID 34170647.
3
Rosenstock J, Wysham C, Frias JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. doi:10.1016/S0140-6736(21)01324-6. PMID 34186022.
4
Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X. PMID 37385275.
5
Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Mol Metab. 2018;18:3-14. doi:10.1016/j.molmet.2018.09.009. PMID 30473097.
6
Eli Lilly and Company. Mounjaro (tirzepatide) injection, prescribing information. Revised April 2026. DailyMed, U.S. National Library of Medicine. NDA 215866, current label.

The disclaimer

Every page is reviewed by medical professionals before it ships, and written with longtime biohackers who were doing this before it was a trend. Reviewed still does not mean prescribed: nothing here is medical advice.

It is research, trial data, and reported use, with the numbers intact so you can check them. For decisions about your body, see a doctor who can look at your labs.